{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:04:46Z","timestamp":1790208286695,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"1DaySooner"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increased availability and cost-reduction of curative hepatitis C therapies and global commitments to elimination through treatment scale-up have made the value proposition for a hepatitis C vaccine unclear. This study aimed to estimate the health impact and benefit-cost ratio of a potential hepatitis C vaccine under different use scenarios.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A compartmental model of hepatitis C transmission, disease progression and care cascade was calibrated to 116 countries, with populations stratified by age, sex, injection drug use status and incarceration status. Model inputs were taken from global datasets (e.g. United Nations, Institute of Health Metrics and Evaluation), published academic literature and WHO reports. Scenarios projected for 2026\u20132050 included: (1) test-treat-vaccinate for people who inject drugs at existing country-specific testing coverage; (2) Scenario 1 plus a one-off test-treat-vaccinate campaign for people who inject drugs; (3) Scenario 2 plus test-treat-vaccinate of prison populations; (4) Scenario 3 plus school-based vaccination; and (5) Scenario 4 plus a five-year adult catch-up campaign. Each scenario\u2019s comparator was a counterfactual with equivalent testing and treatment but no vaccine. Only RNA-negative individuals were eligible for the vaccine (i.e. following negative test or post-treatment), and the vaccine was modelled to increase spontaneous clearance rates to 80% for a mean five-year period. Vaccination costs included commodity (assumed US$5 per person in low and lower-middle income settings, with cost ratio of 1:2:15 for upper-middle and high income settings), service delivery and programmatic costs. Benefits included reduced confirmatory testing, treatment, disease management and productivity losses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Globally, scenarios 1\u20135 averted 1.13\u20138.76\u00a0million infections and 2,490\u201324,100 deaths. Scenarios 1, 2 and 3 had benefit-cost ratios of 2.86, 3.24, and 2.20 respectively. Scenario 4 only had a benefit-cost ratio\u2009&gt;\u20091 for a vaccine with longer duration of protection. Scenario 5 had a benefit-cost ratio\u2009&lt;\u20091 for all characteristics tested.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the context of heterogeneous treatment scale-up among countries, a hepatitis C vaccine is likely to have a positive return-on-investment when used to vaccinate populations at highest risk of infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13858-7","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:53:57Z","timestamp":1783018437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-benefit analysis of a potential hepatitis C vaccine: a modelling study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7614-4997","authenticated-orcid":false,"given":"Farah","family":"Houdroge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Zuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Drummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Zimmer-Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Circe","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"13858_CR1","unstructured":"World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"13858_CR2","unstructured":"World Health Organization. Global health sector strategy on viral hepatitis 2016\u20132021. Geneva: World Health Organization; 2016."},{"key":"13858_CR3","unstructured":"World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"13858_CR4","doi-asserted-by":"crossref","unstructured":"Seung Bum Park, Paul Zimmer-Harwood, T. Jake Liang. Targets of protective immunity and opportunities in hepatitis C virus vaccine development. Nat Rev Immunol. 2026;26(2):112-128.","DOI":"10.1038\/s41577-025-01215-9"},{"issue":"7","key":"13858_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S2468-1253(25)00068-8","volume":"10","author":"L Hiebert-Suwondo","year":"2025","unstructured":"Hiebert-Suwondo L, Manning J, Tohme RA, Buti M, Kondili LA, Spearman CW, et al. A 2024 global report on national policies, programmes, and progress towards hepatitis C elimination: findings from 33 hepatitis elimination profiles. Lancet Gastroenterol Hepatol. 2025;10(7):685\u2013700.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"13858_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12916-015-0440-2","volume":"13","author":"N Scott","year":"2015","unstructured":"Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, et al. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments. BMC Med. 2015;13(1):198.","journal-title":"BMC Med"},{"issue":"1","key":"13858_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12916-019-1411-9","volume":"17","author":"N Scott","year":"2019","unstructured":"Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, et al. The case for a universal hepatitis C vaccine to achieve hepatitis C elimination. BMC Med. 2019;17(1):175.","journal-title":"BMC Med"},{"key":"13858_CR8","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division. World population prospects 2024: online edition. 2024."},{"key":"13858_CR9","unstructured":"World Health Organization, United Nations Children\u2019s Fund. Joint reporting form on immunization (JRF): school vaccination [Internet]. Geneva: World Health Organization; 2025 [cited 2026 Jun 25]."},{"key":"13858_CR10","unstructured":"World Health Organization, United Nations Children\u2019s Fund. Human papillomavirus (HPV) vaccination coverage [Internet]. Geneva: World Health Organization; 2025 [cited 2026 Jun 25]."},{"issue":"34","key":"13858_CR11","doi-asserted-by":"publisher","first-page":"7824","DOI":"10.3748\/wjg.v22.i34.7824","volume":"22","author":"Arnolfo Petruzziello","year":"2016","unstructured":"Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824\u201340. https:\/\/doi.org\/10.3748\/wjg.v22.i34.7824","journal-title":"World J Gastroenterol"},{"key":"13858_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.drugpo.2017.07.006","volume":"47","author":"N Scott","year":"2017","unstructured":"Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy. 2017;47:107\u201316.","journal-title":"Int J Drug Policy"},{"issue":"8","key":"13858_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1136\/gutjnl-2016-311504","volume":"66","author":"N Scott","year":"2017","unstructured":"Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model. Gut. 2017;66(8):1507\u201315.","journal-title":"Gut"},{"key":"13858_CR14","unstructured":"World Health Organization. WHO guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"13858_CR15","unstructured":"Burnet Modelling and Biostatistics Group. Compartmental model and analysis pipeline for hepatitis C (HCV) vaccine evaluations. Melbourne (Australia): Burnet Institute; 2026. https:\/\/github.com\/Burnet-Modelling\/hcv-vaccine."},{"issue":"5","key":"13858_CR16","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2214-109X(23)00057-8","volume":"11","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Global Health. 2023;11(5):e659\u201372.","journal-title":"Lancet Global Health"},{"key":"13858_CR17","unstructured":"Fair H, Walmsley R. World prison population list (14th edition): technical report. London (UK): Institute for Crime & Justice Policy Research; 2024."},{"key":"13858_CR18","unstructured":"Fair H, Walmsley R. World female imprisonment list (6th edition): technical report. London (UK): Institute for Crime & Justice Policy Research; 2025."},{"issue":"8","key":"13858_CR19","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/infdis\/jiw332","volume":"214","author":"M Zeremski","year":"2016","unstructured":"Zeremski M, Dimova RB, Pillardy J, de Jong YP, Jacobson IM, Talal AH. Fibrosis Progression in Patients With Chronic Hepatitis C Virus Infection. J Infect Dis. 2016;214(8):1164\u201370.","journal-title":"J Infect Dis"},{"issue":"1","key":"13858_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","volume":"13","author":"JM Micallef","year":"2006","unstructured":"Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepatitis. 2006;13(1):34\u201341.","journal-title":"J Viral Hepatitis"},{"issue":"8","key":"13858_CR21","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1086\/605947","volume":"200","author":"K Page","year":"2009","unstructured":"Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute Hepatitis C Virus Infection in Young Adult Injection Drug Users: A Prospective Study of Incident Infection, Resolution, and Reinfection. J Infect Dis. 2009;200(8):1216\u201326.","journal-title":"J Infect Dis"},{"issue":"11","key":"13858_CR22","doi-asserted-by":"publisher","first-page":"e27555","DOI":"10.1371\/journal.pone.0027555","volume":"6","author":"CHBS van den Berg","year":"2011","unstructured":"van den Berg CHBS, Grady BPX, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, et al. Female Sex and IL28B, a Synergism for Spontaneous Viral Clearance in Hepatitis C Virus (HCV) Seroconverters from a Community-Based Cohort. PLoS ONE. 2011;6(11):e27555.","journal-title":"PLoS ONE"},{"issue":"1","key":"13858_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/add.14393","volume":"114","author":"J Grebely","year":"2019","unstructured":"Grebely J, Larney S, Peacock A, Colledge S, Leung J, Hickman M, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150\u201366.","journal-title":"Addiction"},{"key":"13858_CR24","doi-asserted-by":"crossref","unstructured":"Hajarizadeh B, Kairouz A, Ottaviano S, Ireland J, Willing A, Cunningham EB, et al. Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(12):e1885-e1898.","DOI":"10.1016\/S2214-109X(23)00461-8"},{"key":"13858_CR25","volume-title":"Global State of Harm Reduction","author":"Harm Reduction International","year":"2024","unstructured":"Harm Reduction International. Global State of Harm Reduction. London: HRI; 2024."},{"issue":"2","key":"13858_CR26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jhep.2025.01.013","volume":"83","author":"HA Razavi","year":"2025","unstructured":"Razavi HA, Waked I, Qureshi H, Kondili LA, Duberg A-S, Aleman S, et al. Number of people treated for hepatitis C virus infection in 2014\u20132023 and applicable lessons for new HBV and HDV therapies. J Hepatol. 2025;83(2):329\u201347.","journal-title":"J Hepatol"},{"issue":"3","key":"13858_CR27","doi-asserted-by":"publisher","first-page":"e0192944","DOI":"10.1371\/journal.pone.0192944","volume":"13","author":"CC Kerr","year":"2018","unstructured":"Kerr CC, Dura-Bernal S, Smolinski TG, Chadderdon GL, Wilson DP. Optimization by Adaptive Stochastic Descent. PLoS ONE. 2018;13(3):e0192944.","journal-title":"PLoS ONE"},{"issue":"Suppl 2","key":"13858_CR28","doi-asserted-by":"publisher","first-page":"i24","DOI":"10.1136\/sextrans-2012-050647","volume":"88","author":"E Fazito","year":"2012","unstructured":"Fazito E, Cuchi P, Mahy M, Brown T. Analysis of duration of risk behaviour for key populations: a literature review. Sex Transm Infect. 2012;88(Suppl 2):i24.","journal-title":"Sex Transm Infect"},{"key":"13858_CR29","unstructured":"CDA Foundation. Hepatitis C \u2013 all countries. Lafayette (CO): CDA Foundation; 2025. Available from: https:\/\/cdafound.org\/polaris\/database-query\/."},{"key":"13858_CR30","doi-asserted-by":"crossref","unstructured":"Vollset SE, Ababneh HS, Abate YH, Abbafati C, Abbasgholizadeh R, Abbasian M, et al. Burden of disease scenarios for 204 countries and territories, 2022\u20132050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204-2256.","DOI":"10.1016\/S0140-6736(24)00932-2"},{"key":"13858_CR31","unstructured":"World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 2nd ed. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"13858_CR32","unstructured":"Clinton Health Access Initiative. HCV market intelligence report. 2023."},{"issue":"10","key":"13858_CR33","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S2468-1253(20)30008-X","volume":"5","author":"N Scott","year":"2020","unstructured":"Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, et al. A model of the economic benefits of global hepatitis C elimination: an investment case. Lancet Gastroenterol Hepatol. 2020;5(10):940\u20137.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"13858_CR34","unstructured":"World Bank Group. World Bank country classifications by income level for 2024\u20132025 [Internet]. Washington (DC): World Bank Group; 2024 [cited 2026 Jun 25]. Available from: https:\/\/blogs.worldbank.org\/en\/opendata\/world-bank-country-classifications-by-income-level-for-2024-2025."},{"key":"13858_CR35","unstructured":"World Health Organization. 2024 MI4A public vaccine purchase dataset. Geneva: World Health Organization; 2024."},{"issue":"12","key":"13858_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S2468-1253(18)30281-4","volume":"3","author":"J Chhatwal","year":"2018","unstructured":"Chhatwal J, Chen Q, Bethea ED, Ladd MA, Mueller PP, Hutin Y, et al. Hep C Calculator: an online tool for cost-effectiveness analysis of DAAs. Lancet Gastroenterol Hepatol. 2018;3(12):819.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"13858_CR37","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4269\/ajtmh.23-0696","volume":"110","author":"Katherine R Dobbs","year":"2024","unstructured":"Dobbs KR, Atieli HE, Valim C, Beeson JG. Previous malaria exposures and immune dysregulation: developing strategies to improve malaria vaccine efficacy in young children. Am J Trop Med Hyg. 2024;110(4):627\u2013630. https:\/\/doi.org\/10.4269\/ajtmh.23-0696","journal-title":"Am J Trop Med Hyg."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13858-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13858-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:37:50Z","timestamp":1790206670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13858-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13858"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13858-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1715"}}